MarginScan™

About NovaScan

NovaScan is a private, pre-revenue diagnostics company pioneering a novel electrical impedance-based platform for rapid, accurate cancer detection. Its primary focus is the development and regulatory clearance of MarginScan™, a device aimed at reducing re-excision rates in surgeries for skin and breast cancer by providing real-time margin assessment. Backed by grant funding, a manufacturing partnership with PHC Group, and a distribution letter of intent with Epredia, NovaScan is targeting its first FDA clearance for skin cancer in early 2027. The company has validated its technology in over 900 patients across multiple cancer types, demonstrating high sensitivity and specificity in clinical studies.

About NovaScan

NovaScan is a private, pre-revenue diagnostics company pioneering a novel electrical impedance-based platform for rapid, accurate cancer detection. Its primary focus is the development and regulatory clearance of MarginScan™, a device aimed at reducing re-excision rates in surgeries for skin and breast cancer by providing real-time margin assessment. Backed by grant funding, a manufacturing partnership with PHC Group, and a distribution letter of intent with Epredia, NovaScan is targeting its first FDA clearance for skin cancer in early 2027. The company has validated its technology in over 900 patients across multiple cancer types, demonstrating high sensitivity and specificity in clinical studies.

Therapeutic Areas